Study on pharmacokinetics of rosuvastatin and its drug interactions with other drugs

Abstract

Abstract: Rosuvastatin, a new generation of statins , has better liver selectivity, less metabolism and long elimination half-life.It has more lipid-lowering effect and a wide range prospects of clinical applications. Moreover, rosuvastatin has good tolerability and the incidence of adverse reactions was similar to other kind of statins. In this paper, rosuvastatin pharmacokinetics and pharmacokinetic interactions with other drugs are reviewed. In order to lay down a solid theory foundation for the guidance in clinical usage of Rosuvastatin, ensure the safety and effectiveness of clinical usage, achieving individualized therapy in its true sense.

Key words: Rosuvastatin, Pharmacokinetics, Drug interaetion

CLC Number:

R969.1

WEN Jin-hua, XIONG Yu-qing. Study on pharmacokinetics of rosuvastatin and its drug interactions with other drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(11): 1309-1314.

References

[1] Cziraky MJ, Willey VJ, McKenney JM, et al. Statin safety: an assessment using an administrative claims database [J]. Am J Cardiol, 2006, 97 (8A) : 61C-68C.
[2] Stang P,Morris L, Kempf J , et al. The cop rescrip tion of contraindicated drugs with statins: continuing potential for increased risk of adverse events[J]. Am J Ther, 2007, 14(1) : 30-40.
[3] Soran H,Durrington P.Rosuvastatin:efficacy,safety and clinical effectiveness[J].Expert Opin Pharmacother, 2008,9(12):2145-2160.
[4] Nezasa K, Higaki K, Hasegawa H, et al.Uptake of of HMGCoA reductase inhibitor ZD 4522 into hepatocytes and distribution into liver and other tissues of the rat [J].Atherosclerosis, 2000,39(2):217-220.
[5] Bolego C, Poli A, Cignarella A,et al. Novel statins: pharmacological and clinical results[J]. Cardiovasc Drugs Ther, 2002, 16(3): 251-257.
[6] Mckenney JM.Efficacy and safety of rosuvastatin in treatment of dyslipidemia[J]. Am J Health Syst Pharm, 2005,62(10):1033-1045.
[7] Warwick MJ, Dane AL, Raza A, et al.Single- and multiple-dose pharmacokinetics and safety of the new HMGCoA reductase inhibitor ZD 4522 [J]. Atherosclerosis, 2000, 151(3):39-43.
[8] Isley WL. Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor[J]. Drugs Today, 2001,37(9): 587-594.
[9] Tan W,LI Y. The role of organic anion transporting polypeptide in drug transport [J].International J Pharm Aceutic Res,2007 , 34 (5) :364-368.
[10] Wen AP,Xu XW.The development of organic anion transporting polypeptide 1B1[J]. Chin Pharm J,2008,43(23):1765-1769.
[11] Zhang W, He YJ. The Pharmacogenetics development of organic anion transporting polypeptide 1B1[J]. Chin J Clin Pharmacol Ther,2008, 13 (7) :721-729.
[12] Pasanen MK, Fredrikson H, Neuvonen PJ,et al. Different effects of slco1b1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin [J].Clin Pharmacol Ther, 2007, 82(6):726-733.
[13] Choi JH, Lee MG, Cho JY,et al. Influence of OATP1B1 Genotype on the Pharmacokinetics of Rosuvastatin in Koreans [J].Clin Pharmacol Ther, 2008 ,83(2):251-257.
[14] Zhang W,Yu BN, He YJ,et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males[J]. Clin Chim Acta, 2006,373(1/2):99-103.
[15] Cooper KJ, Martin PD, Dane AL,et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin [J]. Eur J Clin Pharmacol, 2002 ,58(8): 527-531.
[16] Cooper KJ, Martin PD, Dane AL,et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin [J]. Clin Pharmacol Ther, 2003 ,73(4):322-329.
[17] Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine[J]. Clin Pharmacol Ther, 2004 ,76(2):167-177.
[18] Cooper KJ, Martin PD, Dane AL, et al.The effect of erythromycin on the pharmacokinetics of rosuvastatin [J]. Eur J Clin Pharmacol, 2003, 59(1): 51-56.
[19] Zhang W, Deng S, Chen XP, et al. Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy a randomized, single-blind, placebo-controlled, crossover study[J]. Clin Ther, 2008, 30(7):1283-1289.
[20] Kiser JJ, Gerber JG, Predhomme JA,et al. Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers[J]. J Acquir Immune Defic Syndr, 2008, 47(5):570-578.
[21] Deng JW, Shon JH,Shin HJ,et al. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin[J]. Pharm Res , 2008, 25( 8 ): 1807-1814.
[22] Fan L, Zhang W, Guo D,et al. The effect of herbal medicine baicalin onpharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1[J].Clin Pharmacol Ther, 2008,83(3):471-476.
[23] Schneck DW, Birmingham BK,Zalikowski JA,et al.The effect of gemfibrozil on the pharmacokinetics of rosuvastatin[J]. Clin Pharmacol Ther ,2004, 75(5): 455-463.
[24] Kosoglou T , Statkevich P, Yang B, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin[J]. Curr Med Res Opin, 2004, 20( 8) :1185-1195.
[25] Martin PD, Kemp J, Dane AL,et al. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers[J]. J clin pharmacol, 2002, 42(12):1352-1357.
[26] Simonson SG,Martin PD, Mitchell PD, et al. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics[J]. J Clin Pharmacol, 2005, 45(8): 927-934.